<?xml version='1.0' encoding='utf-8'?>
<document id="10958883"><sentence text="Impact of subdermal norgestrel on hepatic acyl-coenzyme A:cholesterol- acyltransferase (ACAT) activity: possible antiatherogenic effect." /><sentence text="The impact of subdermally placed ethinyl estradiol, norgestrel, and the combination of the two on cholesterol metabolism as measured by hepatic acyl:cholesterol-acyltransferase (ACAT) activity was examined in the rat model"><entity charOffset="33-50" id="DDI-PubMed.10958883.s2.e0" text="ethinyl estradiol" /><entity charOffset="52-62" id="DDI-PubMed.10958883.s2.e1" text="norgestrel" /><entity charOffset="98-109" id="DDI-PubMed.10958883.s2.e2" text="cholesterol" /><entity charOffset="144-148" id="DDI-PubMed.10958883.s2.e3" text="acyl" /><entity charOffset="149-160" id="DDI-PubMed.10958883.s2.e4" text="cholesterol" /><entity charOffset="161-171" id="DDI-PubMed.10958883.s2.e5" text="acyl" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e0" e2="DDI-PubMed.10958883.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e0" e2="DDI-PubMed.10958883.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e0" e2="DDI-PubMed.10958883.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e0" e2="DDI-PubMed.10958883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e0" e2="DDI-PubMed.10958883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e0" e2="DDI-PubMed.10958883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e1" e2="DDI-PubMed.10958883.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e1" e2="DDI-PubMed.10958883.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e1" e2="DDI-PubMed.10958883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e1" e2="DDI-PubMed.10958883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e1" e2="DDI-PubMed.10958883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e2" e2="DDI-PubMed.10958883.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e2" e2="DDI-PubMed.10958883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e2" e2="DDI-PubMed.10958883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e2" e2="DDI-PubMed.10958883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e3" e2="DDI-PubMed.10958883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e3" e2="DDI-PubMed.10958883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e3" e2="DDI-PubMed.10958883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e4" e2="DDI-PubMed.10958883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10958883.s2.e4" e2="DDI-PubMed.10958883.s2.e5" /></sentence><sentence text=" A total of 48 rats were assigned to one of 6 groups, receiving either 0" /><sentence text="1 mg or 1" /><sentence text="0 mg of ethinyl estradiol daily, 1"><entity charOffset="8-25" id="DDI-PubMed.10958883.s5.e0" text="ethinyl estradiol" /></sentence><sentence text="0 or 10 mg of norgestrel daily, and combinations of either 0"><entity charOffset="14-24" id="DDI-PubMed.10958883.s6.e0" text="norgestrel" /></sentence><sentence text="1 mg ethinyl estradiol/1"><entity charOffset="5-22" id="DDI-PubMed.10958883.s7.e0" text="ethinyl estradiol" /></sentence><sentence text="0 mg norgestrel or 1"><entity charOffset="5-15" id="DDI-PubMed.10958883.s8.e0" text="norgestrel" /></sentence><sentence text="0 mg ethinyl estradiol/10 mg norgestrel daily"><entity charOffset="5-22" id="DDI-PubMed.10958883.s9.e0" text="ethinyl estradiol" /><entity charOffset="29-39" id="DDI-PubMed.10958883.s9.e1" text="norgestrel" /><pair ddi="false" e1="DDI-PubMed.10958883.s9.e0" e2="DDI-PubMed.10958883.s9.e0" /><pair ddi="false" e1="DDI-PubMed.10958883.s9.e0" e2="DDI-PubMed.10958883.s9.e1" /></sentence><sentence text=" All drugs were administered through subdermally placed time release capsules" /><sentence text=" The administration of norgestrel only in either 1"><entity charOffset="23-33" id="DDI-PubMed.10958883.s11.e0" text="norgestrel" /></sentence><sentence text="0 mg or 10 mg resulted in significantly lower rates of ACAT activity (0" /><sentence text="77 +/- 0" /><sentence text="566 and 0" /><sentence text="91 +/- 0" /><sentence text="239 pmol/mg/min, respectively)" /><sentence text=" The combination of 1" /><sentence text="0 ethinyl estradiol and 10 mg norgestrel resulted in a significant increase in ACAT activity to 2"><entity charOffset="30-40" id="DDI-PubMed.10958883.s18.e0" text="norgestrel" /></sentence><sentence text="17 +/- 0" /><sentence text="873" /><sentence text=" This combination also resulted in significantly greater weight loss at the conclusion of treatment [247" /><sentence text="83 +/- 6" /><sentence text="2 g (pre) vs" /><sentence text=" 205" /><sentence text="50 +/- 10" /><sentence text="6 (post)]" /><sentence text=" There were no other differences in ACAT activity between groups and no other differences in weight, both between groups and pre- and post-treatment within groups" /><sentence text=" In summary, subdermally placed norgestrel resulted in a significant lowering of ACAT activity not seen with either administration of ethinyl estradiol alone or the combination of ethinyl estradiol and norgestrel in doses ranging from 0"><entity charOffset="32-42" id="DDI-PubMed.10958883.s28.e0" text="norgestrel" /><entity charOffset="134-151" id="DDI-PubMed.10958883.s28.e1" text="ethinyl estradiol" /><entity charOffset="180-197" id="DDI-PubMed.10958883.s28.e2" text="ethinyl estradiol" /><entity charOffset="202-212" id="DDI-PubMed.10958883.s28.e3" text="norgestrel" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e0" e2="DDI-PubMed.10958883.s28.e0" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e0" e2="DDI-PubMed.10958883.s28.e1" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e0" e2="DDI-PubMed.10958883.s28.e2" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e0" e2="DDI-PubMed.10958883.s28.e3" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e1" e2="DDI-PubMed.10958883.s28.e1" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e1" e2="DDI-PubMed.10958883.s28.e2" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e1" e2="DDI-PubMed.10958883.s28.e3" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e2" e2="DDI-PubMed.10958883.s28.e2" /><pair ddi="false" e1="DDI-PubMed.10958883.s28.e2" e2="DDI-PubMed.10958883.s28.e3" /></sentence><sentence text="1 to 1" /><sentence text="0 mg of ethinyl estradiol and 1"><entity charOffset="8-25" id="DDI-PubMed.10958883.s30.e0" text="ethinyl estradiol" /></sentence><sentence text="0 to 10" /><sentence text="0 mg of norgestrel"><entity charOffset="8-18" id="DDI-PubMed.10958883.s32.e0" text="norgestrel" /></sentence><sentence text=" Significantly increased ACAT activity for the combination of 1" /><sentence text="0 ethinyl estradiol and 10 mg norgestrel over either ethinyl estradiol or norgestrel alone or a lower dose combination suggests a dose-related threshold and drug-drug interaction for this effect"><entity charOffset="30-40" id="DDI-PubMed.10958883.s34.e0" text="norgestrel" /><entity charOffset="53-70" id="DDI-PubMed.10958883.s34.e1" text="ethinyl estradiol" /><entity charOffset="74-84" id="DDI-PubMed.10958883.s34.e2" text="norgestrel" /><pair ddi="false" e1="DDI-PubMed.10958883.s34.e0" e2="DDI-PubMed.10958883.s34.e0" /><pair ddi="false" e1="DDI-PubMed.10958883.s34.e0" e2="DDI-PubMed.10958883.s34.e1" /><pair ddi="false" e1="DDI-PubMed.10958883.s34.e0" e2="DDI-PubMed.10958883.s34.e2" /><pair ddi="false" e1="DDI-PubMed.10958883.s34.e1" e2="DDI-PubMed.10958883.s34.e1" /><pair ddi="false" e1="DDI-PubMed.10958883.s34.e1" e2="DDI-PubMed.10958883.s34.e2" /></sentence><sentence text=" These results suggest that subdermally placed norgestrel may result in significantly lower ACAT activity and may have a potential role as an antiatherogenic treatment"><entity charOffset="47-57" id="DDI-PubMed.10958883.s35.e0" text="norgestrel" /></sentence><sentence text="" /></document>